|
||
Article |
| Abstract |
|---|
|
|
|---|
1 h. We find that p60 449-457–H2-Kd complexes retained intracellularly with brefeldin A have a half-life of 30 min, and thus are less stable than surface complexes. While peptide dissociation from retained MHC class I molecules is enhanced, retained H2-Kd molecules maintain a remarkable capacity to bind new T cell epitopes. We find that intracellular H2-Kd molecules can bind new CTL epitopes for up to 3 h after their synthesis. Our studies provide a glimpse of peptide interaction with MHC class I molecules in the endoplasmic reticulum/proximal Golgi complex of intact, infected cells. We propose that the increased intracellular lability of peptide–MHC class I complexes may function to optimize the spectrum of peptides presented to T lymphocytes during cellular infection.
The MHC class I antigen–processing pathway is a constitutive surveillance system that allows CTLs to monitor intracellular proteins (1–3). While the principal purpose of MHC class I antigen presentation is in the defense against viral infection, MHC class I molecules also present peptides derived from bacterial and protozoal pathogens (4). The essential aspects of the MHC class I antigen–processing pathway have been defined. First, endogenous and pathogen-derived proteins in the cytosol are degraded into peptides by the multicatalytic protease complex, or proteasome (5). The precise source of antigenic peptides is somewhat controversial since, in the case of antigens synthesized by the host cell, proteasomes may degrade either the mature protein or defective products generated during translation (6). Peptide fragments are then moved in an ATP-dependent process into the lumen of the endoplasmic reticulum (ER)1 by the transporter associated with antigen processing (TAP, reference 7). While peptides are being generated in the cytosol, MHC class I molecules are being synthesized and inserted into the ER membrane, where they first associate with β2-microglobulin and then TAP in a process that involves calnexin, calreticulin, and a newly described protein called tapasin (8). MHC molecules remain associated with TAP until they bind a peptide, at which time they dissociate from TAP and traffic, as an MHC class I–β2-m–peptide heterotrimer, to the cell surface (9). Although it is clear that antigenic peptides associate with MHC class I molecules in the ER (10), it is unclear how MHC class I molecules manage to selectively capture high affinity peptides. While the function of tapasin in MHC peptide loading is unclear (8), there is evidence that association of MHC class I with TAP may induce a conformational change that makes MHC class I molecules more peptide receptive (11).
In the absence of infection, peptides generated by proteasome-mediated degradation of endogenous proteins are the major substrates transported by TAP and bound by MHC class I H chains (12). Because intracellular pathogens constitute only a very small fraction of the total protein of an infected cell, even in heavily infected cells the majority of peptides associated with MHC class I H chains are derived from the host cell. Although it would be advantageous to the infected host to provide foreign peptides with open access to H chain grooves, it is unclear how accomodating the MHC class I surveillance system is to pathogen derived peptides.
We have used the intracellular pathogen Listeria monocytogenes to investigate the MHC class I antigen–processing pathway. L. monocytogenes is a gram-positive bacterium that causes severe disease in pregnant and immunocompromised individuals (13). Upon phagocytosis by macrophages, L. monocytogenes enters the cytosol by secreting listeriolysin O (LLO), a pore-forming hemolysin which destroys the phagolysosomal membrane (14). Two bacterially secreted proteins, LLO and the murein hydrolase p60, are degraded by proteasomes in the host cell cytosol to form three nonamer peptides: LLO 91-99, p60 217-225, and p60 449-457 (15– 18). These three Listeria-derived peptides are presented to CTL by H2-Kd MHC class I molecules. The number of secreted antigen molecules that the host cell degrades to generate a single H2-Kd-associated epitope ranges from 3–11 (for LLO 91-99 and p60 449-457) to 35 (for p60 217-225) (17, 19, 20). While the majority of antigen molecules that are degraded by the host cell do not yield an antigenic peptide, it is unclear where the losses occur. Each step of the MHC class I antigen–processing pathway, from proteasomemediated antigen degradation to peptide transport by TAP and association with H-2Kd grooves, may exact a substantial loss of epitopes (21–24).
In this report, we investigate the kinetics of CTL epitope generation and loss in L. monocytogenes–infected cells. Because intracellular L. monocytogenes and the host cell are metabolically distinct, it is possible to selectively manipulate antigen production and host cell antigen processing in intact cells with specific inhibitors. We exploit this ability to show that two peptides that are bound with high affinity dissociate from H2-Kd molecules at remarkably different rates. We find that one of the epitopes, p60 217-225, forms a stable complex with H2-Kd while the other epitope, p60 449457 forms a more labile complex with H2-Kd. p60 449457 dissociation occurs more rapidly when H2-Kd molecules are retained within the cell with brefeldin A (BFA) than when they transit to the cell surface, which suggests that intracellular conditions decrease the strength of MHC class I–peptide interactions. Although synthesis of new MHC class I molecules is essential for the generation of CTL epitopes, we find that intracellularly retained MHC molecules continue to bind new L. monocytogenes peptides for up to 3 h. Our findings demonstrate the tremendous capacity of class I molecules to bind pathogen-derived peptides upon cellular infection. Furthermore, enhanced peptide dissociation from MHC class I molecules in the ER/Golgi may enhance cell surface presentation of long-lived epitopes.
Peptides and Reagents.
CTL Assays.
Peptide Competition Assays.
Epitope Extraction and HPLC Fractionation.
Epitope Quantification.
H2-Kd Stability.
Flow Cytometry.
H2-Kd Trafficking.
Monolayers of uninfected or infected J774 cells were washed with PBS and placed in 1 ml of methionine-free medium (methionine-free DMEM with 3% dialyzed FCS, 2 mM L-glutamine, 20 mM Hepes, pH 7.5). After 30 min, 50 µCi [35S]methionine (translabel, ICN Biomedicals Inc., Irvine, CA) was added and cells were pulse labeled for 15 min. Chases were performed in 4 ml RP10–, and 20 µg/ml tetracycline was added to L. monocytogenes–infected cells. Cells were lysed on ice in 1 ml lysis buffer (1% Triton X-100 in 140 mM NaCl, 10 mM Tris-HCl, pH 7.4 [Tris-buffered saline] with 0.5 mM PMSF and 0.1 mM N
![]()
Materials and Methods
Top
Abstract
Materials and Methods
Results
Discussion
References
Bacteria and Cell Lines.
L. monocytogenes strain 43251 was obtained from the American Type Culture Collection (Rockville, MD) and grown in brain hearth infusion. H2-Kd-transfected RMA-S cells (25) were provided by M. Bevan (University of Washington, Seattle, WA) and grown in HL-1 medium (BioWhittaker, Inc., Walkersville, MD) with 400 µg/ml G418 (GIBCO BRL, Gaithersburg, MD). Macrophage cell line J774 (BALB/c, H-2d) and the mastocytoma cell line P815 (DBA/2, H-2d) (both from American Type Culture Collection) were grown in RPMI 1640 (GIBCO BRL) with 10% FCS, 2 mM L-glutamine, 20 mM Hepes (pH 7.5), 50 µM 2-mercaptoethanol, penicillin, streptomycin, and gentamicin (RP10 media). CTL clones L12.3, L9.6, and WP11.12 were derived from L. monocytogenes–primed C57BL/6 x BALB/c (H-2bxd) mice and maintained as described (16). L12.3 is specific for LLO 91-99, L9.6 is specific for p60 217-225, and WP11.12 is specific for p60 449-457, each in the context of the H2-Kd molecule.
Synthetic LLO 91-99 (GYKDGNEYI), p60 217-225 (KYGVSVQDI), and p60 449-457 (IYVGNGQMI) peptides were purchased from Research Genetics, Inc. (Huntsville, AL). Peptides were HPLC purified and quantified by amino acid analysis and mass spectrometry. BFA was purchased from Epicentre Technologies (Madison, WI) and cycloheximide (CHX) and anisomycin (ANM) from Sigma Chemical Co. (St. Louis, MO).
CTL assays were performed as previously described (16). In short, 104 [51Cr]sodium chromate P815 target cells were added to HPLC-fractionated peptides or synthetic peptides dissolved in PBS. CTL were added at an E/T ratio of 1–3:1 and the assays were incubated for 4–5 h at 37°C. Supernatants were assayed for 51Cr-release in a gamma counter. The percentage of specific lysis was determined as described previously (15).
To estimate the affinity of H2-Kd for p60 217-225 and p60 449-457, P815 target cells were incubated in the presence of 10–10 M LLO 91-99 and a range of either p60 217-225 or p60 449-457 concentrations. Target cells were incubated with peptides for 30 min before the addition of CTL clone L12.3 (specific for LLO 91-99) at an effector to target ratio of 2:1. The percent specific lysis was determined 4 h after the addition of CTL.
J774 cells were grown to confluence in 27-ml RP10 media without antibiotics (RP10–) in 150-mm tissue-culture plates. Cells were infected with 3 ml of a log phase culture of L. monocytogenes (OD600 of 0.1) for 30 min. The media was then replaced with RP10– containing 5 µg/ml gentamicin. Infected J774 macrophages were harvested by scraping with PBS, pelleted by centrifugation, and stored at –80°C. To extract peptides, pellets were resuspended in 10 ml 0.1% TFA, dounce homogenized, sonicated, and centrifuged, at 100,000 g for 35 min at 4°C. Supernatants were lyophilized, pellets were resuspended in 0.1% TFA, spun through a Centricon-10 membrane, and fractionated by reverse-phase HPLC using a 0–60% acetonitrile gradient. Separated peptide fractions were lyophilized and used for CTL assays (16).
Lyophilized HPLC fractions were dissolved in 200 µl PBS. Samples of 5–50 µl were loaded on P815 target cells and tested for the presence of LLO 91-99, p60 217225, or p60 449-457 with CTL clones L12.3, L9.6, and WP11.12, respectively. Peptide-containing fractions were titrated and assayed in triplicate along with standard concentrations of synthetic peptides. Molar amounts of peptide were determined and epitope numbers were calculated as described (16).
RMA-S Kd cells were seeded in the wells of 24-well plates at a concentration of 106 cells/ml (1 ml/well) in serum-free HL-1 medium with 400 µg/ml G418. Cells were incubated with 30 µM synthetic LLO 91-99, p60 217-225, or p60 449-457, or without peptide at 37°C overnight (o/n). Cells were harvested, washed three times with PBS, and chased at 37°C in the absence of peptide. Samples were taken after 0, 2, 4, and 6 h, washed with ice-cold PBS with 0.5% bovine serum albumin and 0.02% NaN3 (PBS buffer) and stained for H2-Kd class I expression.
4 x 105 cells were incubated with an excess amount of SF1-1.1.1 (a conformation-dependent mAb specific for the H2-Kd
3 domain) or without antibody for 30 min on ice. Cells were washed with PBS buffer and then incubated with FITCconjugated goat anti–mouse Ig for 30 min, washed twice, and then fixed in 1% paraformaldehyde in PBS. Fluorescence was measured with a FACScan® flow cytometer and data were analyzed using the CELLQuest application programs (Becton Dickinson, Mountain View, CA).
H2-Kd was metabolically labeled and immunoprecipitated as previously described (26). In short, 2–4 x 106 J774 cells were seeded in 25-cm2 tissue-culture flasks in 10 ml RP10 media without antibiotics (RP10–) and incubated at 37°C o/n. Cells were infected with 1 ml of log phase L. monocytogenes (OD600 of 0.1) for 30 min, washed with PBS, and placed in RP10– with 50 µg/ml gentamicin for 3 h.
-p-tosyl-L-lysine chloromethyl ketone), and the detergent lysates were centrifuged (6 min, 14,000 rpm at 4°C) and precleared with 25 µl protein A–Sepharose (50% slurry) and 5 µl mouse IgG for 4 h at 4°C. H2-Kd was immunoprecipitated with 25 µl protein A–Sepharose and 5 µl SF11.1.1 (1.4 mg/ml) for 30 min at 4°C. Sepharose beads were washed with Tris-buffered saline/0.5% Triton X-100, resuspended in endoglycosidase H (endo H) buffer (0.1 M phosphate buffer, pH 6.5, 0.5% SDS), and boiled for 2 min. The samples were split; half was mock-digested, and the other half digested with 2 x 10–3 U endo H at 37°C o/n. Sample buffer was added and proteins were separated on 10% polyacrylamide gels under reducing conditions. Radioactive signals were enhanced by incubation with 0.5 M salicylate for 15 min and visualized by autoradiography.
![]()
Results
Top
Abstract
Materials and Methods
Results
Discussion
References
Kinetics of CTL Epitope Loss from L. monocytogenes–infected Cells.
In previous studies we have shown that p60 449457 is generated in L. monocytogenes infected J774 cells earlier and faster than p60 217-225 (17). During the first few hours of infection,
10 times as much p60 449-457 can be extracted from infected cells as p60 217-225. Since both peptides derive from the same antigen and bind to H2-Kd molecules, the difference in numbers is attributable to a greater efficiency of p60 449-457 generation (17). To determine if MHC–peptide complex stability plays a role in the kinetics of p60 217-225 and p60 449-457 accumulation in L. monocytogenes–infected cells, we treated cells with tetracycline, which rapidly inhibits bacterial protein synthesis. Epitopes were quantified at hourly intervals after the cessation of antigen synthesis. In agreement with previous findings (19), we found that p60 217-225 epitope numbers are stable in infected cells (Fig. 1 A). However, the number of p60 449-457 epitopes that can be extracted from infected cells after tetracycline treatment drops abruptly, from 9,000 epitopes/cell to only 1,000 epitopes/cell 3 h later (Fig. 1 B). In the absence of tetracycline, p60 217-225 levels continue to increase in number between 4 and 7 h of cellular infection. In contrast, the number of p60 449-457 epitopes per cell remains stable between 5 and 7 h after infection in the absence of tetracycline. Taken together, our results indicate that the plateau levels of p60 449-457 epitopes during the later stages of cellular infection reflect an equilibrium, with equal amounts of p60 449-457 being generated and lost within infected cells.
|
p60 449-457 Dissociates More Readily from H2-Kd than LLO 91-99 or p60 217-225.
The most likely explanation for the rapid loss of p60 449-457 from tetracyclinetreated cells is that p60 dissociates from H2-Kd and is destroyed by intra- and extracellular proteases. To determine if the two p60 epitopes and LLO 91-99 (which forms stable complexes with H2-Kd in infected cells; reference 20) differ in their dissociation from class I molecules, we incubated H2-Kd–transfected RMA-S cells with the three L. monocytogenes peptides o/n and then determined the stability of surface H2-Kd expression by flow cytometry. All three peptides stabilized surface H2-Kd after o/n incubation (Fig. 1 D). However, when cells were incubated at 37°C in the absence of peptides, surface H2-Kd complexes generated with p60 449-457 were markedly less stable than those generated with either LLO 91-99 or p60 217-225 (Fig. 1 D). These findings suggest that the loss of p60 449-457 in infected cells results from the enhanced dissociation of p60 449-457 relative to the other two epitopes. The decrease in surface expression of H2-Kd complexes with LLO 91-99 and p60 217-225 detected in this assay probably results from (a) the early loss of peptides that were only partially bound, (b) the more prolonged decrease attributable H2-Kd dilution caused by continued cell division, and (c) the intrinsic turnover rate of peptide-stabilized H2-Kd. The finding that H2-Kd complexes with p60 449-457 appear to be more stable in the RMA-S-Kd assay than p60 449-457 in infected cells, likely results from an overestimation of peptide-containing surface complexes on RMA-S cells, since MHC class I molecules may be detected by conformationspecific antibody for some time after peptide dissociation.
Enhanced Dissociation of p60 449-457 from H2-Kd Molecules in the ER/Golgi.
Since H2-Kd molecules travel to the cell surface rapidly in L. monocytogenes–infected cells (26), the majority of CTL epitopes extracted from tetracyclinetreated infected cells are likely to come from cell-surface H2-Kd. Thus, the 1 h half-life of p60 449-457 in infected cells principally reflects cell surface dissociation of p60 449457 from H2-Kd. We decided to determine if the stability of intracellular MHC peptide complexes is similar to surface complexes. BFA is an antibiotic that disrupts the Golgi complex, thereby preventing the movement of ER contents to the cell surface (27). BFA does not detectably affect L. monocytogenes multiplication, protein synthesis, or protein secretion (results not shown). We investigated the trafficking of metabolically labeled H2-Kd in L. monocytogenes– infected J774 cells in the absence and presence of BFA. In the absence of BFA, the great majority of pulse labeled H2Kd becomes endo H resistant after a 2 h chase, indicating that the complexes have trafficked through the Golgi complex (Fig. 2). In the presence of BFA, however, immunoprecipitated H2-Kd molecules remain endo H–sensitive, indicating that they have not traversed the Golgi complex (Fig. 2). It is noteworthy that retained H2-Kd molecules are stable, with minimal loss during the 4-h chase period.
|
60% more p60 449-457 epitopes were extracted from BFA-treated cells 6–7 h after infection than from untreated cells. This finding may be attributable to unusually high concentrations of H2-Kd and β2-microglobulin in the ER (28). To determine the stability of p60 217-225 and p60 449-457 when H2-Kd is retained intracellularly, we inhibited L. monocytogenes protein synthesis in infected, BFA treated cells and quantified epitope numbers. Surprisingly, although the amount of p60 217-225 decreased only minimally (Fig. 3 C), the loss of p60 449-457 in BFAtreated cells was very rapid (Fig. 3 D). The half-life of p60 449-457 associated with retained and normally trafficking H2-Kd molecules is shown in Table 1. In three separate experiments, the half-life of p60 449-457 in BFA-treated cells was reduced by
50%. Thus, in L. monocytogenes–infected cells, p60 449-457–H2-Kd complexes are less stable intracellularly than on the cell surface.
|
|
|
|
| Discussion |
|---|
|
|
|---|
The rate of antigenic peptide dissociation from MHC class I molecules determines the density of surface complexes available for T lymphocyte detection. Stable MHC class II– peptide complexes, for example, persist on the cell surface longer, giving them a greater opportunity to be of immunologic significance (29). In this report we demonstrate that epitope dissociation from naturally loaded MHC class I molecules can vary dramatically between peptides that appear, by competition assays, to have similar affinities for the class I molecule. The prevalence of p60 449-457 in infected cells is greater than either LLO 91-99 or p60 217225 throughout cellular infection because p60 449-457 is processed very efficiently (17). When p60 synthesis is made transient by tetracycline treatment of infected cells, the prevalence of p60 217-225 becomes greater than p60 449457 within several hours (Fig. 1). Thus, differences in peptide–MHC stability during continuous antigen production are less apparent than when antigen production is transient, as is typical of many viral infections. In the case of EpsteinBarr virus infection, the disparate amount of two EpsteinBarr virus epitopes has been attributed to different stabilities of their respective complexes with HLA-A11 (30).
Although it is unclear how important epitope density is in determining the magnitude of CTL responses after infection, it is very likely that differences in the half-lives of antigenic complexes on the cell surface will have implications for CTL responses. After infection with L. monocytogenes, H2-Kd–p60 217-225 will be present much longer than H2-Kd–p60 449-457 complexes. The importance of H2-Kd/peptide stability may be reflected by the finding that, after murine infection with L. monocytogenes, the number of CTL responding to p60 217-225 is 10 times greater than the number responding to p60 449-457 (31). A correlation between MHC–peptide stability and immunodominance has been suggested by an analysis of peptides that varied in their dissociation rate from MHC class I molecules (32).
While the selective presentation of epitopes that are stably bound by MHC class I molecules might enhance the T cell response to an intracellular pathogen, there is no known mechanism in the ER for differentiating high offrate from slow off-rate peptides. To increase the likelihood that an MHC class I molecule will bind a slow off-rate peptide, accelerated peptide dissociation from MHC class I molecules in the ER would be advantageous. Our finding that the half-life of intracellularly retained H2-Kd–p60 449457 is decreased suggests that such a mechanism may exist. How dissociation of p60 449-457 from H2-Kd is enhanced intracellularly is unknown. It is possible that physiologic conditions in the ER result in MHC class I conformations that loosen the association between the H chain groove and the antigenic peptide. Alternatively, ER resident proteins may enhance dissociation of fast off-rate peptides. In the MHC class II antigen processing pathway, the HLA-DM molecule catalyzes dissociation of invariant chain derived CLIP peptides from MHC class II molecules and facilitates loading with antigenic peptides (33–36). Recent studies indicate that HLA-DM may selectively enhance the dissociation of peptides with rapid off-rates (37). Whether the more rapid dissociation of low affinity peptides from class I molecules in the ER results from a similar interaction with a chaperone molecule, or perhaps tapasin, remains to be examined.
Current models of MHC class I antigen processing propose that newly synthesized MHC class I molecules form a complex with β2-microglobulin and associate with TAP molecules in the ER. When the MHC class I–β2-microglobulin complex binds a peptide, the trimeric complex dissociates from TAP and travels to the cell surface. The length of time from H chain synthesis to emigration from the ER varies with the different allotypes of MHC class I, but generally occurs within 30–60 min. In the context of the rapid association of MHC class I molecules with endogenous peptides, our finding that intracellularly retained H2-Kd molecules can bind additional p60 217-225 and p60 449-457 for up to 3 h after their synthesis is remarkable (Fig. 4). Since the length of time that retained H2-Kd molecules can bind new CTL epitopes significantly exceeds the residence time of H2-Kd in the ER in the absence of BFA, our findings suggest that MHC class I molecules may bind different peptides sequentially. This suggests that enhanced dissociation of fast off-rate peptides in the ER may liberate MHC class I molecules for subsequent interactions with better, slower off-rate peptides.
Based on our data, we propose the following model for MHC class I antigen presentation. J774 cells constitutively synthesize H2-Kd molecules at a high rate that exceeds the rate of high affinity, slow off-rate endogenous peptide production. As a consequence, newly synthesized H2-Kd molecules bind TAP-translocated peptides of varying affinities and off-rates. In the absence of higher affinity or slower off-rate peptides, H-2Kd molecules with fast off-rate peptides travel to the cell surface where their more rapid turnover is inconsequential. Upon cellular infection, however, new peptides are generated and offered to MHC class I molecules. The best peptides to present will be those that form the most stable complex on the cell surface with MHC class I molecules. We suggest that the ER provides a microenvironment in which fast off-rate peptides dissociate more readily, giving slow off-rate peptides a selective advantage to reach the cell surface.
| Acknowledgments |
|---|
We would like to thank Peter Cresswell and members of his laboratory for helpful discussions during the course of this work.
Submitted: 3 December 1996
Revised: 14 January 1997
| References |
|---|
|
|
|---|
1 Braciale TJ & Braciale VL. Viral antigen presentation and MHC assembly, Sem Immunol, 1992, 4, 81–84.[Medline]
2 Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation, Cell, 1994, 76, 287–299.[Medline]
3 Yewdell JW & Bennink JR. Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule–restricted T lymphocytes, Adv Immunol, 1992, 52, 1–123.[Medline]
4 Kaufmann SHE. CD8+ T lymphocytes in intracellular microbial infections, Immunol Today, 1990, 11, 129–136.[Medline]
5 Goettrup M, Soza A, Kuckelkorn U & Kloetzel P-M. Peptide antigen production by the proteasome: complexity provides efficiency, Immunol Today, 1996, 17, 429–435.[Medline]
6 Yewdell JW, Anton LC & Bennink JR. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? , J Immunol, 1996, 157, 1823–1826.[Abstract]
7 Androlewicz MJ & Cresswell P. How selective is the transporter associated with antigen processing? , Immunity, 1996, 5, 1–5.[Medline]
8 Sadasivan B, Lehner PJ, Ortmann B, Spies T & Cresswell P. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP, Immunity, 1996, 5, 103–114.[Medline]
9 Ortmann B, Androlewicz MJ & Cresswell P. MHC class I/β2-microglobulin complexes associate with TAP transporters before peptide binding, Nature (Lond), 1994, 368, 864–867.[Medline]
10 Lapham CK, Bacik I, Yewdell JW, Kane KP & Bennink JR. Class I molecules retained in the endoplasmic reticulum bind antigenic peptides, J Exp Med, 1993, 177, 1633–1641.
11 Day PM, Esquivel F, Lukszo J, Bennink JR & Yewdell JW. Effect of TAP on the generation and intracellular trafficking of peptide-receptive major histocompatibility complex class I molecules, Immunity, 1995, 2, 137–147.[Medline]
12 Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D & Goldberg AL. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules, Cell, 1994, 78, 761–771.[Medline]
13 Gellin BG & Broome CV. Listeriosis, JAMA (J Am Med Assoc), 1989, 261, 1313–1320.
14 Bielecki J, Youngman P, Connelly P & Portnoy DA. Bacillus subtilis expressing a haemolysin gene from Listeria monocytogenescan grow in mammalian cells, Nature (Lond), 1990, 345, 175–176.[Medline]
15 Pamer EG, Harty JT & Bevan MJ. Precise prediction of a dominant class I MHC–restricted epitope of Listeria monocytogenes. , Nature (Lond), 1991, 353, 852–855.[Medline]
16 Pamer EG. Direct sequence identification and kinetic analysis of an MHC class I–restricted Listeria monocytogenesCTL epitope, J Immunol, 1994, 152, 686–694.[Abstract]
17 Sijts AJAM, Neisig A, Neefjes J & Pamer EG. Two Listeria monocytogenesCTL epitopes are processed from the same antigen with different efficiencies, J Immunol, 1996, 156, 685–692.
18 Sijts AJAM, Villanueva MS & Pamer EG. CTL epitope generation is tightly linked to cellular proteolysis of a Listeria monocytogenesantigen, J Immunol, 1996, 156, 1497–1503.[Abstract]
19 Villanueva MS, Fisher P, Feen K & Pamer EG. Efficiency of MHC class I antigen processing: a quantitative analysis, Immunity, 1994, 1, 479–489.[Medline]
20 Villanueva MS, Sijts AJAM & Pamer EG. Listeriolysin is processed efficiently into an MHC class I–associated epitope in Listeria monocytogenes–infected cells, J Immunol, 1995, 155, 5227–5233.[Abstract]
21 Niedermann G, Butz S, Ihlenfeldt HG, Grimm R, Lucchiari M, Hoschützky H, Jung G, Maier B & Eichmann K. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules, Immunity, 1995, 2, 289–299.[Medline]
22 Ossendorp F, Eggers M, Neisig A, Ruppert T, Goettrup M, Sijts A, Mengedé E, Kloetzel P-M, Neefjes J, Koszinowski U & Melief C. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation, Immunity, 1996, 5, 115–124.[Medline]
23 Gournier H, Pascolo S, Siegrist CA, Jehan J, Perarnau B, Garcia Z, Rose T, Neefjes J & Lemonnier TA. Restriction of self-antigen presentation to cytolytic T lymphocytes by mouse peptide pumps, Eur J Immunol, 1995, 25, 2019–2026.[Medline]
24 Chen W, Khilko S, Fecondo J, Margulies DH & McClukey J. Determinant selection of major histocompatibility complex class I–restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues, J Exp Med, 1994, 180, 1471–1483.
25 Ljunggren, H.G., C. Öhlen, P. Höglund, L. Franksson, and K. Kärre. 1991. The RMA-S lymphoma mutant: consequences of a peptide loading defect on immunological recognition and graft rejection. Int. J. Cancer. (Suppl.)6:38–44.
26 Villanueva MS, Beckers CJM & Pamer EG. Infection with Listeria monocytogenesimpairs sialic acid addition to host cell glycoproteins, J Exp Med, 1994, 180, 2137–2145.
27 Klausner RD, Donaldson JG & Lippincott-Schwartz J. Brefeldin A: insights into the control of membrane traffic and organelle structure, J Cell Biol, 1992, 116, 1071–1080.
28 Wiertz EJHJ, Jones TR, Sun L, Bogyo M, Geuze HJ & Ploegh HL. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol, Cell, 1996, 84, 769–779.[Medline]
29 Nelson CA, Petzold SJ & Unanue E. Peptides determine the lifespan of MHC class II molecules in the antigen-presenting cell, Nature (Lond), 1994, 371, 250–252.[Medline]
30 Levitsky V, Zhang Q-J, Levitskaya J & Masucci MG. The life span of major histocompatibility complex–peptide complexes influences the efficiency of presentation and immunogenicity of two class I–restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4, J Exp Med, 1996, 183, 915–926.
31 Vijh, S., and E.G. Pamer. 1997. Immunodominant and subdominant CTL responses to Listeria monocytogenes infection. J. Immunol. In press.
32 van der Burg SH, Visseren MJW, Brandt RMP, Kast WM & Melief CJM. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC–peptide complex stability, J Immunol, 1996, 156, 3308–3314.[Abstract]
33 Denzin LK & Cresswell P. HLA-DM induces CLIP dissociation from MHC class II
β dimers and facilitates peptide loading, Cell, 1995, 82, 155–165.[Medline]
34 Fung-Leung W-P, Surh CD, Liljedahl M, Pang J, Leturcq D, Peterson PA, Webb SR & Karlsson L. Antigen presentation and T cell development in H-2-M–deficient mice, Science (Wash DC), 1996, 271, 1278–1281.[Abstract]
35 Sherman MA, Weber DA & Jensen PE. DM enhances peptide binding to class II MHC by release of invariant chain–derived peptide, Immunity, 1995, 3, 197–205.[Medline]
36 Sloan VS, Cameron P, Porter G, Gammon M, Amaya M, Mellins E & Zaller DM. Mediation by HLA-DM of dissociation of peptides from HLA-DR, Nature (Lond), 1995, 375, 802–806.[Medline]
37 Weber DA, Evavold BD & Jensen PE. Enhanced dissociation of HLA-DR–bound peptides in the presence of HLA-DM, Science (Wash DC), 1996, 274, 618–620.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|